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Abstract
Studies in rodents have demonstrated that insulin in the central nervous system induces satiety. In humans, these effects
are less well established. Insulin detemir is a basal insulin analog that causes less weight gain than other basal insulin
formulations, including the current standard intermediate-long acting Neutral Protamine Hagedorn (NPH) insulin. Due to its
structural modifications, which render the molecule more lipophilic, it was proposed that insulin detemir enters the brain
more readily than other insulins. The aim of this study was to investigate whether insulin detemir treatment differentially
modifies brain activation in response to food stimuli as compared to NPH insulin. In addition, cerebral spinal fluid (CSF)
insulin levels were measured after both treatments. Brain responses to viewing food and non-food pictures were measured
using functional Magnetic Resonance Imaging in 32 type 1 diabetic patients, after each of two 12-week treatment periods
with insulin detemir and NPH insulin, respectively, both combined with prandial insulin aspart. CSF insulin levels were
determined in a subgroup. Insulin detemir decreased body weight by 0.8 kg and NPH insulin increased weight by 0.5 kg
(p= 0.02 for difference), while both treatments resulted in similar glycemic control. After treatment with insulin detemir, as
compared to NPH insulin, brain activation was significantly lower in bilateral insula in response to visual food stimuli,
compared to NPH (p= 0.02 for right and p= 0.05 for left insula). Also, CSF insulin levels were higher compared to those with
NPH insulin treatment (p= 0.003). Our findings support the hypothesis that in type 1 diabetic patients, the weight sparing
effect of insulin detemir may be mediated by its enhanced action on the central nervous system, resulting in blunted
activation in bilateral insula, an appetite-regulating brain region, in response to food stimuli.
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Introduction
In addition to its blood glucose lowering peripheral effects,
insulin acts within the central nervous system (CNS) to regulate
eating behavior and energy balance [1]. Animal studies have
shown that disrupted intracerebral insulin signaling causes weight
gain and that intracerebroventricular insulin administration
reduces food intake and body weight [2,3]. In humans, central
insulin action was studied using intranasal insulin [4]; acute
intranasal insulin promoted satiety and reduced snacking in the
postprandial state in women [5] and resulted in weight loss in the
longer term in men [6]. However, it is not clear whether effects of
intranasal insulin are completely independent of insulin’s periph-
eral action. Besides, intranasal insulin is not clinically available.
Patients with type 1 diabetes (T1DM) require treatment with
multiple subcutaneous insulin injections daily. Insulin detemir (ID)
is a more recently developed basal insulin analog, that has been
associated with body weight loss compared to weight gain after
treatment with other basal insulin formulations [7]. ID differs from
human insulin in that threonine at position B30 has been removed
and that lysine at B29 has been acylated with myristic acid, a 14-
carbon fatty acid. This fatty-acid moiety stabilizes ID self-
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association and enables the binding to albumin, which gives ID its
long-acting properties [8]. It has been hypothesized [9] that due to
the fatty acid moiety, ID more easily enters the brain, thereby
potentially promoting satiety in relevant CNS regions and
reducing appetite, food intake and body weight. Accordingly, ID
may have stronger effects in modulating brain functions than other
long-acting insulin formulations: ID, administered intravenously,
enhanced cortical activity compared to human insulin (as
measured by electroencephalography, EEG and magnetoenceph-
alography, MEG) and decreased food intake in both preclinical
[10] and clinical studies [11,12]. However, the effects of ID on
appetite regulating brain regions during food stimuli have not been
studied and no data are available regarding insulin concentrations
in human cerebrospinal fluid (CSF) during insulin treatment and
its relation to insulin’s central actions.
In previous functional MRI (fMRI) studies, it was shown that
obese subjects show hyperactivation to food pictures in brain
networks linked to motivation, reward and cognitive control
[13,14] and that fMRI hyperactivation to high-calorie food
pictures predicts weight gain [15]. In the present study, fMRI
was used to test the hypothesis that treatment with ID modifies
activation in appetite regulating brain regions in response to visual
food stimuli compared to regular treatment with Neutral
Protamine Hagedorn insulin (NPH). The study was performed
in T1DM patients since these patients are insulin-deficient,
allowing the assessment of effects attributable to exogenous insulin
per se. Indeed, differences were observed in brain activation
between treatment with ID and NPH.
Materials and Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethics statement
The study was approved by the Medical Ethics Review
Committee of the VU University Medical Center (VUMC) and
the Central Committee on Research involving Human Subjects;
the study was conducted according to the Declaration of Helsinki.
All participants gave written informed consent before inclusion in
the study.
Participants
From January 2009 until May 2011, 36 T1DM men were
included in the study (Figure 1). The last follow-up visit was on 13
December 2011. Patients (aged 18–60 years; BMI 18–35 kg/m2)
were recruited from the outpatient clinic, from neighboring
hospitals and through advertisements in local newspapers. All
subjects underwent a screening visit, consisting of medical history
taking, physical examination and fasting blood and urine analyses.
Exclusion criteria were a history of cardiovascular, renal and liver
disease, severe head trauma, neurological or psychiatric disorders,
endocrine diseases not well-controlled for the last three months,
inability to undergo MRI scanning, substance abuse or the use of
anticoagulants, oral steroids or any centrally acting agent. In
addition diabetes duration less than 1 year, glycated hemoglobin
HbA1c.8.5% (69 mmol/mol), a history of or current proliferative
retinopathy, a history of recurrent severe hypoglycemia (defined as
an episode that requires external assistance to aid recovery), or a
medical history of hypoglycemia unawareness were exclusion
criteria. Any current insulin therapy was allowed, as long as
patients were willing to switch to the basal-bolus study insulin
treatment.
Protocol and intervention
This study was part of the INcEREBRO study (ClinicalTrials.-
gov, NCT00626080) and was conducted according to a cross-over
design (Figure 2). After a run-in period of at least four weeks,
during which their current insulin therapy was optimized, patients
were randomly assigned to start with either ID or NPH in the
evening, in combination with insulin aspart at mealtimes.
Randomization (block design) was conducted by the Trial
Pharmacy of the VUMC and the assigned treatments were
concealed by envelopes. Since NPH and ID can be visually
distinguished as NPH is a cloudy solution that needs to be mixed
before injection, while the ID preparation is available as a clear
solution, blinding of insulin treatment was not possible. After each
12-week treatment-period patients underwent an fMRI. Also,
immediately after the MRI measurement, a lumbar puncture (LP)
was performed to obtain CSF for measurement of insulin levels.
Undergoing an LP was made optional, and was performed only in
a subgroup of patients who signed an additional informed consent.
All participants received detailed information about the
scanning procedure, but were not aware of the food-related
nature of the experiment, to avoid anticipation. They were
instructed to refrain from eating, alcohol or coffee from 10 PM the
night before scanning. Patients were instructed to inject their basal
insulin and, if possible, not to use any insulin aspart after their
dinnertime injection. They were instructed to measure their blood
glucose at home and send the value via text message to the
research physician in order to receive further instructions if
necessary; they arrived at the hospital at 7.15 AM. Upon arrival,
in all participants blood was drawn and blood glucose level was
checked and corrected if necessary (when glucose was,4 mmol/L
and/or falling [relative to early morning self-monitored glucose
levels], glucose was injected intravenously; no insulin aspart was
injected); just before and immediately after the MRI glucose was
measured as well.
Questionnaires
Before and directly after scanning, patients completed ques-
tionnaires rating hunger, fullness, appetite, prospective consump-
tion, desire to eat and thoughts of eating on a 10-point Visual
Analog Scale as well as a shortened version of the profile of mood
Figure 1. Participant flow diagram. ID, insulin detemir; NPH,
Neutral Protamine Hagedorn insulin; QC, quality control.
doi:10.1371/journal.pone.0094483.g001
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state (POMS) before and after scanning [16]. Furthermore,
patients completed the DTSQ (Diabetes Treatment Satisfaction
Questionnaire) [17] and the Dutch Eating Behaviour Question-
naire (DEBQ) [18] once.
fMRI paradigm
The fMRI task consisted of the presentation of four types of
pictures, showing 1) high calorie food, 2) low calorie food, 3) non-
food objects and 4) arrows, adapted from [19]. Pictures were
assembled both from commercial stock photography websites and
from self-made pictures. All pictures were full-color, high
resolution photographs, showing the four types of pictures either
in an indoor or an outdoor background, resulting in eight different
combinations, i.e. high calorie x indoor, high calorie x outdoor,
low calorie x indoor, low calorie x outdoor, non-food x indoor,
non-food x outdoor, arrow left and arrow right (presented via
Eprime software [19]).
Participants were placed in a supine position in the scanner with
their head placed in a passive restraint (pads around the head) to
minimize motion. fMRI was performed while the subjects were
presented the above described visual stimuli using a projector and
screen system viewed through a mirror. Before image acquisition
started, participants performed a test task to ensure that the task
was understood properly. The real task consisted of eleven pseudo-
randomized blocks, each block containing three to eight different
pictures of the same category. In order to control for attention
lapses, participants were requested to make indoor-outdoor
judgments using an MRI-compatible response box. Each block
was followed by one to three scrambled arrows (left or right), to
which participants had to respond by indicating the direction of
the arrow. Each stimulus (picture and arrow) was shown for four
seconds, followed by an inter-stimulus interval (fixation cross) of
1.5 to 2.5 seconds. The task lasted approximately eight minutes.
Since each patient was scanned twice, two different versions of the
task, with equal design, were presented. The order of scanning
versions was randomized across subjects, to prevent order effects.
Image acquisition and analysis
MRI data were acquired on a 3.0 T GE SignaHDxt scanner
(General Electric, Milwaukee, Wisconsin, USA). A 3-D structural
MRI was obtained using a T1-weighted FSPGR (fast Spoiled
Gradient echo) sequence with the following parameters: TR
(Repetition Time) = 7.8 ms; TI (Inversion Time) = 450 ms; TE
(Echo Time) = 3.0 ms; FA (flip angle) = 12o; voxel size
= 160.9460.94 mm. fMRI data were acquired using echo planar
imaging (EPI) T2* BOLD (Blood Oxygen Level Dependent) pulse-
sequence (TR=2160 ms, TE=30 ms, matrix 64664, 211 mm2
field of view, 40 slices angled parallel to the planum sphenoidale,
3 mm thickness, 0 mm gap).
Image data were analyzed using SPM8 software (Wellcome
Trust Center for Neuroimaging, UK). The origin of each MR
volume was aligned to the anterior commissure. Series were
corrected for differences in slice acquisition times and were
realigned to the first volume. T1-coregistered volumes were
normalized to Montreal Neurological Institute (MNI) space,
resliced to 36363 mm voxels and spatially smoothed using an
8mmfull width at half maximum Gaussian kernel. After high-pass
filtering (cut-off 128 s), functional scans were analyzed in the
context of the general linear model using box-car functions
convolved with a canonical hemodynamic response function to
model responses during each block. For each subject, activation
contrasts were computed. Contrast images derived from first-level
(within subject) analyses were entered into second level (between
subject) (random effects) analyses. Paired t-tests were performed
for treatment effect, masked with main effect of contrast. A priori
regions of interest (ROIs) were determined based on areas
activated by cues of food rewards in previous studies (i.e., insula,
striatum, orbitofrontal cortex). When ROIs corresponded to
discrete anatomical structures, small volume correction, using
5 mm (for anterior cingulate cortex, ACC) or 10 mm (for insula)
radius spheres [20], was used for multiple comparisons applied at
p,.05.
Biochemical analyses
Capillary blood glucose was measured using a calibrated blood
glucose meter (OneTouch ultra easy, LifeScan, Inc. Milpitas, CA,
USA). HbA1c was measured in the VUMC central laboratory, by
cation-exchange chromatography (reference value: 4.3–6.1% (23–
43 mmol/mol); Menarini Diagnostics, Florence, Italy). Serum
insulin concentrations were quantified using an immunometric
assay. (Centaur, Siemens Diagnostics, Deerfield, IL). Cross-
reactivity was calculated using the slope of the Passing &Bablok
analysis. Cross-reactivity was 100% for NPH and 120% for ID.
CSF samples were centrifuged at 2750 RPM for 10 min at 4uC,
within one hour after collection. A small amount of CSF was used
for routine analysis, including total cell count, total protein and
glucose. CSF was aliquoted in polypropylene tubes of 0.5 mL and
stored at280uC until further analysis [21]. CSF insulin levels were
measured using an ultrasensitive RIA (EMD Millipore, Billerica,
MA).Cross-reactivity of NPH and ID were 140% and 20%,
Figure 2. Study design. After a run-in period, patients were randomly assigned to treatment with either insulin detemir or NPH insulin. After each
treatment period an fMRI-scan was acquired. During the fMRI, pictures were shown of four categories in random order (HC, high calorie food; LC, low
calorie food; N, non-food; A, arrow).
doi:10.1371/journal.pone.0094483.g002
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respectively. Cholesterol (total, HDL, triglycerides) was measured
using an enzymatic calorimetric assay (Modular P, Roche
Diagnostics, Basel, Switzerland). Urine microalbumin was quan-
tified using immunonephelometry (Immage 800, Beckman Coul-
ter, Brea, CA).
Statistical analysis
Clinical data are expressed as mean 6 SD, skewed data and
ordinal values are expressed as median and inter-quartile range.
Treatment effects were analyzed using repeated measure analysis,
or Wilcoxon signed-rank test. Univariate correlations (Pearson’s r
or Spearman’s r) were used to examine associations. Analyses were
run on SPSS (SPSS Inc., Chicago, IL), version 20. p,.05 was
considered statistically significant.
The effects of two different insulin regimens on fMRI-measured
BOLD signal have not been investigated before. Other fMRI
studies using a parallel group or paired designs to compare two
groups or post-pre intervention, respectively, required 6-26
individuals to show meaningful results [15,22,23]. Based on these
studies and our premise that the difference on brain activation
between the two insulin regimens would be modest (15%, standard
deviation 20%), and assuming a power of .8 and a two-sided .05
significance level, we calculated that in a cross-over study design
30 patients would be needed.
Results
Patient disposition and baseline characteristics
Thirty-seven patients were screened, of whom 36 were included
and subsequently randomized (Figure 1). One patient dropped out
of the study in the third week of treatment due to difficulties with
NPH regimen adjustments. Three fMRI sessions had to be
discarded (one because of excessive patient movement, two due to
technical problems). Consequently, given the cross-over design,
the corresponding sessions of these patients had to be excluded as
well. Thus, 32 T1DM men were included in fMRI analyses
(Table 1). Of these patients, 19 previously used insulin glargine, 10
ID and 3 NPH insulin before inclusion in the study.
Clinical effects of ID versus NPH
ID decreased, whereas NPH increased body weight in T1DM
patients (Table 2). Daily insulin doses and HbA1c were similar
after each treatment period. Mean glucose and insulin levels
during fMRI are listed in Table 2. In the subgroup of patients that
consented to undergo an LP (n=11 paired LP), serum insulin
levels were slightly, yet significantly higher after treatment with ID
versus NPH (p= .04), while CSF insulin levels for ID were
substantially higher than for (p= .003; Table 2); CSF to serum
insulin ratios were 0.075 versus 0.12 for NPH and ID respectively
(p= .1) Blood glucose levels and CSF glucose levels were not
different between treatments. CSF routine analyses did not show
any abnormalities.
As assessed by the DTSQ, perceived hyperglycemia and
hypoglycemia did not differ significantly between treatments.
Patient satisfaction was significantly greater when using ID versus
NPH. No differences in eating behavior were found (DEBQ). ID
treatment trended towards less hunger, appetite and desire to eat
after the scan compared to NPH treatment (p= .10, p= .07 and
p= .09, respectively). During fMRI, patients treated with ID
classified 87.864.6% of all food and non-food items correctly
(indoor versus outdoor classification), compared to 89.066.4%
with NPH insulin treatment (NS). Response times were similar in
both treatment groups for all picture categories.
Main results: CNS effects of ID versus NPH
In both treatment groups, increased activation (higher BOLD
signal) was observed in the ventral visual stream (occipital lobe)
when viewing pictures (all categories) compared to baseline (i.e.
pictures of an arrow), and in the food versus non-food contrast as
well. Irrespective of treatment, T1DM patients showed an
increased activation in the left ventral insula upon viewing food
versus non-food items (Table 3, main effects of task).
Treatment with ID versus NPH resulted in significantly lower
brain activation in bilateral insula when viewing food versus non-
food items (p=0.02, Z=3.33 for right and p=0.05, Z=2.90 for
left insula; Table 3, group effects; Figure 3), which was unaltered
after correction for plasma glucose and insulin levels (data not
shown). BOLD signal change in bilateral insula was positively
associated with change in body weight after NPH (r= .51, p= .003
for right insula and r= .35, p= .05 for left insula). BOLD signal
was not associated with change in body weight after treatment
with ID (r=2.19, p= .30 for right insula and r=2.16, p= .40 for
left insula). In the subgroup of patients that consented to undergo
an LP, no correlations were observed between BOLD signal and
CSF insulin levels or change in body weight after either treatment.
There were no between-treatment differences when viewing high-
calorie compared to low-calorie food items (data not shown).
Discussion
Using a cross-over design in T1DM patients, we confirmed
modest weight reduction after an ID-based versus NPH-based
insulin treatment regimen [7,24], but expanded these observations
by showing significantly lower brain activation in bilateral insula in
response to visual food stimuli during ID therapy. Interestingly, in
a subgroup of patients, we found higher serum and CSF insulin
levels after ID than after NPH treatment.
The insula, the region in which lower BOLD signal was
observed, is relevant in the processing of food cues and craving for
food [25] and is assumed to be involved in food choices [26].
Insulin acts in the CNS to induce satiety and inhibit food intake
and weight gain, and insulin receptors are also present at high
concentrations in the cerebral (insular) cortex, and are accessible
via the CSF [27]. Therefore, ID may have both direct and indirect
effects on the insula, ultimately resulting in reduced neural
activation and suppression of the BOLD signal.
Table 1. Patient characteristics.
N 32
Age (years) 36.369.4
Diabetes duration (years) 13.068.6
Body weight (kg) 83.3613.9
BMI (kg/m2) 25.263.3
Systolic blood pressure (mmHg) 118610.3
Diastolic blood pressure (mmHg) 77.867.1
HbA1c (%) (mmol/mol) 7.460.6 (5766.6)
Total Cholesterol (mmol/L) 4.560.6
HDL Cholesterol (mmol/L) 1.560.4
LDL Cholesterol (mmol/L) 2.560.5
Triglycerides (mmol/L) 1.160.5
Urine albumin: creatinine ratio (mmol/mg) 1.162.7
doi:10.1371/journal.pone.0094483.t001
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Whether the lower BOLD activation during visual food stimuli
after ID treatment is cause or consequence of the observed weight
loss cannot be determined from our study. Two prospective studies
[15,20] however, demonstrated that enhanced brain responses to
food cues can predict future weight gain. Further evidence for a
direct effect of ID on the CNS comes from studies using systemic
infusions in mice and humans which resulted in acute changes in
EEG and MEG as well as ensuing reductions in food intake [10–
12].
Interestingly, a positive correlation was found between BOLD
signal in bilateral insula and treatment-related body weight change
only after treatment with NPH. Although no definite causal
relationship may be inferred from this finding, it may be
speculated that NPH modifies food-related activity in appetite
regulating brain regions in a way that promotes weight gain.
Studies in mice investigating whether or not ID crosses the
blood-brain-barrier used acute infusions and showed conflicting
results: in one study a prefential brain tissue effect of ID was found
after intravenous insulin injection, whereas in the other study it
was shown that ID does not cross the mouse blood-brain-barrier at
all [10,28]. In humans, information on CSF insulin levels during
treatment with various insulin formulations is lacking. Since (long-
Table 2. Patient characteristics at baseline and at 12 week of intervention.
NPH ID P
T1DM patients, n =32
Body weight (kg), t = 0 weeks 83.4613.7 83.7613.8 0.3
Body weight (kg), t = 12 weeks 83.9614.2 83.0613.7 0.007
Mean change in body weight (kg) 0.5462.0 20.7661.7 0.02
HbA1c (%) (mmol/mol), t = 0 weeks 7.360.6 (5666.6) 7.460.7 (5767.7) 0.6
HbA1c (%) (mmol/mol), t = 12 weeks 7.460.6 (5766.6) 7.460.6 (5766.6) 0.8
Mean change inHbA1c (%) (mmol/mol) 0.03860.39 (0.464.4) 0.003160.42 (0.064.6) 0.8
Daily insulin dose (basal) (IU/day), t = 12 weeks 27.8612.9 27.7611.2 0.9
Daily insulin dose (aspart) (IU/day), t = 12 weeks 32.1612.7 31.7612.2 0.7
Mean blood glucose at MRI (mmol/L) 10.464.0 8.863.6 0.05
Serum insulin level at MRI (pmol/L) 74.4 (47.1–121.4) 93.6 (61.1–119.9) 0.2
Subgroup (that underwent lumbar puncture), n = 11
Mean blood glucose at MRI (mmol/L) 11.463.9 9.564.3 0.2
Mean CSF glucose at MRI (mmol/L) 5.262.2 5.861.4 0.5
Serum insulin level at MRI (pmol/L) 64.6 (44.2–77.3) 68.7 (57.0–106.9) 0.04
CSF insulin level at MRI (pmol/L) 4.8 (4.4–5.0) 8.3 (7.4–8.6) 0.003
doi:10.1371/journal.pone.0094483.t002
Table 3. fMRI data.
NPH insulin Insulin detemir
L/R coordinates Z score p value L/R coordinates Z score p value
x y z x Y z
Main effect of task: All versus baseline
Occipital cortex L 230 246 217 .8 ,0.001 L 230 285 13 .8 ,0.001
R 39 279 13 .8 ,0.001 R 36 282 10 .8 ,0.001
R 30 261 217 .8 ,0.001 R 39 282 25 .8 ,0.001
Main effect of task: Food versus non-food
Occipital cortex L 215 282 214 7.15 ,0.001 L 212 288 211 6.10 ,0.001
L 212 291 25 7.05 ,0.001 L 212 294 22 5.87 ,0.001
R 9 279 28 7.19 ,0.001 R 9 282 28 6.47 ,0.001
Ventral insula L 230 26 28 3.43 NS L 233 29 25 2.65 NS
R 36 26 10 3.71 NS
Group effects: Food versus non-food: NPH . detemir
Insula R 36 210 211 3.33 0.02
L 239 210 1 2.90 0.05
Coordinates of peak cluster activity from the normalized brain based on the Montreal Neurological Institute (MNI) system; ROI, region of interest.
doi:10.1371/journal.pone.0094483.t003
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standing) T1DM is associated with absence of endogenous insulin
production, patients with T1DM seem an attractive model to
determine CSF insulin levels that should entirely reflect the result
of exogenous administration of insulin. Although our study is the
first to perform LP procedures to this end in T1DM, due to the
associated discomfort and potential side-effects, a relatively small
number of patients consented to undergo this procedure twice
during the course of the study. Nevertheless, in this relatively small
sample, increased CSF insulin levels were found in patients treated
with ID versus NPH, in spite of comparable daily basal insulin
doses, supporting the hypothesis that ID crosses the BBB more
readily than NPH, or that clearance of ID from the CSF occurs at
a slower rate.
In the present study we focused on ID action in the brain, but
other mechanisms underlying its weight reducing effect have been
proposed, e.g. increased energy expenditure and reduced
frequency of hypoglycemia. However, in a randomized cross-over
study [29] comparing ID and NPH insulin treatment no difference
in energy expenditure between both treatments was observed.
Since ID treatment results in more stable insulin levels and a
greater effect on glucose metabolism in the liver than in peripheral
tissues [30], it has also been suggested that the weight difference
between NPH and ID is due to a reduced frequency of
hypoglycemia with ID [31]. As patients not systematically reported
all hypoglycemias (and snacking) during the present study, we
cannot rule out that a reduced hypoglycemia (and snacking)
frequency caused the differences in body weight. However, this
hypothesis is unlikely to fully explain the weight-sparing effect of
ID, as supported by the fact that other studies demonstrated that
insulin glargine, when causing the same frequency of hypoglyce-
mia as ID, resulted in more weight gain.
Limitations of the study include the non-blinded study design:
NPH and ID can be visually distinguished as NPH is a cloudy
solution that needs to be mixed before injection, while the ID
preparation is available as a clear solution. However, worldwide,
NPH is the standard (intermediate) long-acting human insulin and
therefore the best active comparator. Moreover, since subjects
were not aware of the food-related nature of the experiment, it is
unlikely that knowledge of the type of insulin treatment has
influenced the BOLD effects in our study. Additionally, possible
confounders that could have accounted for the observed differ-
ences in CNS responses to food cues include HbA1c or prevailing
glucose and/or insulin plasma levels. We deliberately chose to
study patients in a real-life setting as compared to an acute
exposure (e.g. clamp condition), since it is unclear whether this
artificial condition can be extrapolated to real-life conditions in
Figure 3. Increased activation in bilateral insula when watching food versus non-food pictures after treatment with NPH versus ID.
SPM images for illustrative purposes. Increased activation after NPH treatment compared to ID treatment is shown in right (upper panel) and left
insula (lower panel) respectively (crosshair); colour bar represents t value for paired Student’s t test. In the graphs on the right the BOLD signal
intensity (effect size) for each group is plotted (arbitrary units), mean 6 SEM; NPH, NPH insulin; ID, insulin detemir.
doi:10.1371/journal.pone.0094483.g003
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which weight differences are observed. In the present study,
adjustment for glycemic variables and insulin levels did not alter
the fMRI-measured results. Preferably, a cross-over trial should
have a wash-out period to avoid carry-over effects. However, since
all type 1 diabetes patients need some type of long-acting insulin
every day, insulin washout was not an option. An alternative
option to minimize carry-over effects is to lengthen treatment
periods [32]. In our study, we lengthened the period of both
treatments from the originally planned 8 weeks to 12 weeks. Since
the duration of action of NPH and ID on glucose metabolism is
less than 24 h, we expect that lengthening the treatment period to
12 weeks was sufficient. Weight gain associated with insulin
treatment is relevant for both T1DM and type 2 diabetic (T2DM)
patients although this side effect of insulin treatment may be more
relevant in T2DM patients who generally are already overweight
or obese. Although it is tempting to generalize our findings to
T2DM, this study should be repeated in T2DM patients in future
investigations.
In summary, the present study expands the limited data
available, describing the effects of insulin on the human brain.
We showed that a 12-week treatment with ID, compared to NPH,
resulted in weight loss in T1DM patients, which was paralleled by
decreased brain activation in the bilateral insula in response to
visual food stimuli. Furthermore, ID versus NPH treatment
resulted in elevated CSF insulin levels. These findings support the
hypothesis that the weight sparing effect of ID may, at least in part,
be mediated by its enhanced action in the CNS that interferes with
food-related activation in appetite regulating brain regions.
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